News and Trends 20 Nov 2023 M&As: what’s up with the ADC buying spree? …biotech Orum Therapeutics’ ADC candidate is proof of this. The anti-CD33 antibody-enabled GSPT1 degrader, ORM-6151, received U.S. Food and Drug Administration (FDA) clearance to pursue phase 1 trials for treating… November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2017 French Biotech Strikes Deal with Novo Nordisk for New Cancer Drug …Pharma has in-licensed a new clinical-stage antibody candidate from Novo Nordisk to reinforce its position in the crowded space. In exchange for its anti-C5aR antibody, IPH5401, Novo Nordisk gets a… June 6, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2019 MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II …target of the drug, and MorphoSys, which generated antibody candidates for the target. Several months after the pair reported positive phase I results last year, Novartis licensed the drug in… October 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 10 immunotherapy companies making waves in 2023 …solid tumors. The drug is a monoclonal antibody, which is a type of protein that can bind to antigens of cancer cells; flagging the cells and could trigger the destruction… March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Dec 2017 Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017 …results. Its candidate, ABX464, caused a significant reduction of viral reservoirs over a 28-day period. The study included just 11 patients, with 9 completing the study and 8 of those… December 18, 2017 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 16 Jul 2025 Eight rare autoimmune diseases biotechs are fighting to treat …two candidates for Graves’ disease: batoclimab and IMVT-1402. In September 2024, the company reported positive phase 2a results from a clinical trial investigating the monoclonal antibody batoclimab in patients with… July 16, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Mar 2024 6 biotech companies tackling antibiotic resistance …a pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms, with a near-term focus on challenging respiratory infections. Clarametyx’s lead candidate is an immune-enabling antibody therapy… March 7, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 30 Nov 2023 Could an Alzheimer’s vaccine make treatment more affordable? …Reuters report, AC Immune is challenging this rhetoric. The Swiss company’s phase 1/2 ABATE trial is testing its Alzheimer’s vaccine candidate ACI-24.060 in patients with Down’s syndrome. The candidate is… November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 28 May 2025 New weight loss drugs: Biotech’s mission to end obesity …Viking’s candidate appeared to have “outmaneuvered” amycretin. Biopharma giant Amgen is also seeing positive results for its most advanced obesity asset MariTide, a monoclonal antibody linked to a pair of… May 28, 2025 - 17 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2022 GATC AI platform reduces time to find opioid use disorder candidates …candidates’ safety and efficacy in reducing opioid consumption, withdrawal symptoms and relapse. To discover these specific drug candidates for OUD, GATC obtained addiction drug target biomarkers from Liquid Biosciences, an… October 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 Jun 2024 Eight companies tackling cancer with allogeneic cell therapy in 2024 …candidates are engineered T cells designed to express the Tmod receptors, enabling them to differentiate between cancerous and non-cancerous cells. This selective targeting aims to reduce off-target effects and improve… June 13, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Mar 2024 Are these T cell receptor (TCR) therapy companies on your radar? …and allogeneic candidates as well as antibody-like TCR bispecifics, called T cell Engaging Receptors (TCER). TCERs are biologics that are designed to bind T cells to target and destroy cancer… March 28, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email